Chapter 37 The Nervous System in Systemic Lupus Erythematosus John G. Hanly, MD INTRODUCTION Although neurological (N) and psychiatric (P) events are frequently encountered in patients with systemic lupus erythematosus…
Chapter 46 Cytotoxic Drug Treatment Eva D. Papadimitraki, MD , Dimitrios T. Boumpas, MD, FACP INTRODUCTION Cytotoxic agents were initially introduced for their ability to interrupt nucleic acid and protein…
Chapter 34 Gastrointestinal Disease in Systemic Lupus Erythematosus Chi Chiu Mok, MD, FRCP INTRODUCTION Gastrointestinal (GI) manifestations of systemic lupus erythematosus (SLE) are protean. Any part of the GI tract,…
Chapter 48 New Treatments in Systemic Lupus Erythematosus Vasileios C. Kyttaris, MD , George C. Tsokos, MD INTRODUCTION Immunosuppressive therapy, the main treatment modality for severe lupus, has been effective…
Chapter 45 Systemic Steroids Mustafa Al-Maini, MD , Murray Urowitz, MD INTRODUCTION Corticosteroid medications are found in the therapeutic armamentarium of most medical specialties. Rheumatologists have had a long relationship…
Chapter 38 Overlap Syndromes, Mixed Connective Tissue Disease, and Undifferentiated Connective Tissue Disease Robert W. Hoffman, DO INTRODUCTION Classification of the rheumatic diseases continues to be challenging for a number…
Chapter 42 Neonatal Lupus: Clinical Perspectives Anca D. Askanase, MD, MPH , Jill P. Buyon, MD INTRODUCTION Neonatal lupus (NL) is a model of passive autoimmunity; anti-SSA/Ro-SSB/La antibodies (Ab) cross…
Chapter 22D Antibodies to SSA/Ro and SSB/La: Potential Mechanisms of Tissue Injury in Neonatal Lupus-Congenital Heart Block Jill P. Buyon, MD , Robert M. Clancy, PhD PATHOGENESIS: LAYING THE GROUNDWORK…
Chapter 22C Antineuronal Antibodies John G. Hanly, MD INTRODUCTION Autoantibody production is a cardinal feature in the pathogenesis of systemic lupus erythematosus (SLE) and is associated with most of the…
